Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
P. Fenaux,G. Mufti,16 Authors,L. Silverman
2009 · DOI: 10.1016/S1470-2045(09)70003-8
The Lancet Oncology · 2,433 Citations
TLDR
Treatment with azacitidine increases overall survival in patients with higher-risk myelodysplastic syndromes relative to conventional care.